Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 ex991-q2earningsrelease2026.htm EX-99.1 Document Exhibit 99.1 Media Contact: 858-366-6900 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2026 Financial Results San Diego, August 6, 2026 - Tan
EX-99.1 2 ex991-q2earningsrelease2026.htm EX-99.1 Document Exhibit 99.1 Media Contact: 858-366-6900 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2026 Financial Results San Diego, August 6, 2026 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights • Sales of $254.6 million worldwide, including $179.3 million in the United States (U.S.) • Gross margin of 57%, up 460 basis points compared to second quarter 2025 • Pump shipments of more than 33,000 pumps worldwide, including 22,000 pumps in the U.S. • Operating margin improved 800 basis points compared to second quarter 2025 • Scaled pay-as-you-go reimbursement mode...
Source
Exhibit EX-99.1
0001438133-26-000124
Filed August 6, 2026 at 8:08 PM UTC. The figures above are from the audited statements, not from this release.